The short version of c-Met signaling fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Some opioid antagonists are not pure antagonists because they produce weak opioid partial agonist effects, and can produce analgesic effects when administered in high doses to individuals who have never taken opioids. Examples of such compounds include nalorphine and levallorphan. However, the analgesic effects from these specific drugs are limited and tend to be accompanied by dysphoria, most likely due to additional agonist action at the κ-opioid receptor. As they induce opioid withdrawal effects in people who are taking, or have recently used, opioid full agonists, these drugs are generally considered to be antagonists for practical purposes. The weak partial agonist effect can be useful for some purposes, and has previously been used for purposes such as long-term maintenance of former opioid addicts using nalorphine, however it can also have disadvantages such as worsening respiratory depression in patients who have overdosed on non-opioid sedatives such as alcohol or barbiturates. On the other hand, Naloxone has no partial agonist effects, and is in fact a partial inverse agonist at μ-opioid receptors, and so is the preferred antidote drug for treating opioid overdose. Naloxone and naltrexone are commonly used opioid antagonist drugs which are competitive antagonists that bind to the opioid receptors with higher affinity than agonists but do not activate the receptors. This effectively blocks the receptor, preventing the body from responding to opioids and endorphins. Naloxone is a drug used to treat opioid overdose.
Testosterone is available for transdermal administration in the form of gels, creams, scrotal and non-scrotal patches, and axillary solutions. Transdermal testosterone gel has a bioavailability of about 8 to 14% when administered to recommended skin sites including the abdomen, arms, shoulders, and thighs. Scrotal skin is the thinnest skin of the body and has enhanced absorption characteristics relative to other skin areas. Application of testosterone gels and creams to the scrotum has been studied and achieves much higher levels of testosterone than conventional skin sites. Scrotal application of testosterone requires approximately 5-fold lower doses relative to non-scrotal application. The development of transdermal preparations of testosterone (and of progesterone) has been more difficult than the case of estradiol. This is because testosterone levels in men are about 100 to 1,000 times higher than estradiol levels in women (300 to 1,000 ng/dL vs. 50 to 150 pg/mL, respectively). Non-scrotal testosterone patches were assessed and were found to be ineffective in raising testosterone levels in men. As a result, scrotal testosterone patches were initially marketed. Subsequently, however, non-scrotal testosterone patches with special permeation enhancers that could successfully increase testosterone levels were developed and marketed. However, non-scrotal testosterone patches nonetheless require a large skin area for application (up to 60 cm2) and must be replaced daily.
In November 2020, Hetero signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture more than 100 million doses of Sputnik V, the world’s first registered COVID-19 vaccine. Hetero continued its response to COVID-19 with the launch of Movfor (molnupiravir) in late 2021 and Nirmacom (a generic version of nirmatrelvir-ritonavir) in 2022. In December 2022, Nirmacom became the first generic adaptation of the COVID treatment to receive WHO prequalification, allowing Hetero to distribute it to 95 LMICs under a voluntary license administered through the Medicines Patent Pool. 2023- Present In 2023, Hetero celebrated 30 years of its journey from a small-time API producer to a global pharmaceutical manufacturing powerhouse. In 2024, Hetero entered a partnership with Gilead Sciences to expand availability of Lenacapavir, a long acting injectable HIV treatment, across 120 high-incidence countries in order to support the global HIV response. In 2025, Hetero opened a new commercial office in Warsaw, Poland, marking the company’s formal entry into the Eastern European pharmaceutical markets. In 2026, Hetero launched generic versions of semaglutide - the active ingredient in medicines for type 2 diabetes and obesity management- in emerging markets under the names Truglyx, Rolmodl, and Moto G.
Sources: en.wikipedia.org
7-Eleven has a major presence in the Republic of Korea convenience store market, where it competes with CU, GS25 (formerly LG25), and independent competitors. There are 11,067 7-Eleven stores in the Republic of Korea; with only Japan and Thailand hosting more stores. The first 7-Eleven store in the Republic of Korea opened in May 1989 in Songpa-gu in Seoul with a franchise license under the Lotte Group. In January 2010, Lotte Group acquired the Buy the Way convenience store chain and rebranded its 1,000 stores under the 7-Eleven brand. In 2021, 7-Eleven announced that it would be working with a South Korean nonprofit to create jobs and franchising opportunities for North Korean defectors in South Korea. In January 2022, Lotte acquired the entire stake of Ministop Korea Co. for 313.37 billion won ($263 million). After acquisition, all the Ministop store were gradually converted to 7-Eleven.
== Cut flowers and cut greens == Plants used for cut flowers and cut greens are derived from many plant species and diverse plant families. Cut flower arrangements can include cut stems from annual plants, flower bulbs or herbaceous perennials, cut stems of evergreens or colored leaves, flowers from landscape shrubs, flowers that have been dried or preserved, fruit on tree branches, dried uniquely shaped fruit or stems from plants, unique dried weeds (sometimes painted to add a distinctive touch), etc. These plants come from diverse natural habitats, so different environmental conditions are used to grow them. The cut flower plants that were first used in the development of the floral industry in northern Europe were those adapted to the cool temperatures that occur there. On the other hand, the warmer temperatures of Southeast Asia, led to the development of different plants adapted to those conditions. The floral industry was primarily local, wherever in the world, until the 1950s. The advent and development of international trade and transportation changed the cut flower segment of the floral industry. Cut flowers could be grown cheaply in a cool or warm region of the world and shipped to markets in population centers anywhere. This started in the cool coastal regions of California but quickly expanded into the mountains of Colombia, Ecuador, Kenya, Ethiopia, China, Mexico, etc., and to distinctive environments in Indonesia, South Africa, Hawaii, Australia, New Zealand, etc.
=== 2000–present === In September 2002, Lilly partnered with Amylin Pharmaceuticals to develop and commercialize Amylin's new drug based on exendin-4, a novel substance isolated from the venom of the Gila monster. Exenatide, the first of the GLP-1 receptor agonists, was approved by the US Food and Drug Administration in April 2005. In 2003, Lilly introduced Cialis (tadalafil), a competitor to Viagra for erectile dysfunction developed in a partnership with Icos. Cialis maintains an active period of 36 hours, causing it sometimes to be dubbed the "weekend pill". It was advertised during the 2004 Super Bowl XXXVIII and 2005 Super Bowl XXXIX halftime shows. In 2004, Lilly introduced duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder. It ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis. In January 2007, Lilly acquired Icos for $2.1 billion, after raising its offer and facing opposition from Institutional Shareholder Services. Lilly subsequently closed Icos' manufacturing operations, terminated nearly 500 Icos employees, leaving 127 employees working at the biologics facility. In December 2007, CMC Biopharmaceuticals A/S (CMC), a Copenhagen-based provider of contract biomanufacturing services, bought the Bothell, Washington-based biologics facility from Lilly and retained the existing 127 employees.
The probiotic The effect of Lactobacillus reuteri is attributed to immunomodulating substances that inhibit the production of the cytokine TNF (tumor necrosis factor) in humans. Examination of the membrane lipids of various strains of Lactobacillus reuteri shows that only the TNF-inhibiting strains have lactobacillic acid. In this experiment, the cfa gene was also inactivated in a lactobacillic acid-producing bacterial strain and the mutants were cultivated. The supernatant was tested in a cell culture and - in contrast to the supernatant of the wild type - suppresses the production of TNF. However, the addition of lactobacillic acid as a pure substance does not lead to the inhibition of cytokine production. Thus, the fatty acid is only indirectly involved in the immunomodulatory activity of L. reuteri; an altered membrane fluidity is cited as a possible explanation.
Sources: en.wikipedia.org
In the pancreas, osteocalcin acts on beta cells, causing beta cells in the pancreas to release more insulin. In fat cells, osteocalcin triggers the release of the adiponectin hormone, which increases insulin sensitivity. In muscle, osteocalcin acts on myocytes to promote energy availability and utilization and, in this manner, favors exercise capacity. In the testes, osteocalcin acts on Leydig cells, stimulating testosterone biosynthesis and affecting male fertility. In the brain, osteocalcin plays an important role in development and functioning, including spatial learning and memory. An acute stress response (ASR), colloquially known as the fight-or-flight response, stimulates osteocalcin release from bone within minutes in mice, rats, and humans. Injections of high levels of osteocalcin alone can trigger an ASR in the presence of adrenal insufficiency.
==== Assisted death in Canada ==== A lethal dose of propofol is used for medical assistance in dying in Canada to induce deep coma and death quickly, but rocuronium is always given as a paralytic, ensuring death, even when the patient has died as a result of an initial propofol overdose.
Nucleic acid analogues are compounds which are structurally analogous to naturally occurring RNA and DNA, through substitutions of any of its sugar, phosphate, and nucleobase components. They are used in medicine and in molecular biology research.
In 2019, the FDA issued a drug safety warning about serious breathing difficulties in patients using pregabalin or gabapentin, particularly when combined with opioids or other CNS depressants. A 2022 meta-analysis found that combination therapy with opioids and gabapentinoids could be associated with an increased risk of CNS depression and mortality, and concluded that combination therapy with these medications requires close clinical monitoring. Combined use of pregabalin and alcohol produces additive impairment of cognitive and psychomotor function, as both substances act as central nervous system depressants. The pregabalin prescribing information advises against alcohol consumption during treatment, noting that the CNS depressant effects of the two substances compound one another. The combination of pregabalin and benzodiazepines produces additive CNS and respiratory depression, with pregabalin pharmacodynamically augmenting benzodiazepine sedation. A 2020 study published in the British Journal of Anaesthesia examining gabapentinoid prescribing trends in Scotland found that among recurrent gabapentinoid users, benzodiazepines were co-prescribed in 26.8% of cases, opioids in 49.9%, and both in a further 17.1%, and that the age-standardised death rate among those prescribed gabapentinoids was double that of the general Scottish population. The prescribing information for pregabalin advises monitoring for respiratory depression and sedation when co-prescribing with benzodiazepines.
HIV infection In October 2016, scientists from Emory University and National Institute of Allergy and Infectious Diseases (NIAID) published a paper which claimed that they applied daily ART (antiretroviral therapy) of 90 days followed by simianized (rhesus macaques) anti α4β7 antibody on SIV+ rhesus macaques for 23 weeks. Twenty three months after stopping both ART and anti-α4β7 antibody treatment, the in vivo SIV level still remained undetectable. Therefore, treating HIV+ people with ART and anti-α4β7 simultaneously may be a new therapy that could potentially lead to an HIV infection cure. In mice, vedolizumab was not able to prevent or control HIV-infections. Phase 1 clinical trial of that therapy has been initialized by NIAID since May 2016. For each of the participants, they will get vedolizumab infusions every four weeks for 30 weeks. Before the 23rd week of vedolizumab infusions, cART (combination ART) is kept. During the 30 weeks, blood draws are repeated for baseline tests. After the 22-week-cART is stopped, both viral load and CD4 count will be monitored biweekly. If HIV viral load goes high or their CD4 cell counts decrease by too much when vedolizumab is used alone, cART will be brought back on the participants. The published results from this clinical trial suggest "that blockade of α4β7 may not be an effective strategy for inducing virological remission in HIV-infected individuals after ART interruption" because only one patient showed prolonged virus suppression.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.